Compound class:
Synthetic organic
Comment: TBI-223 is an oxazolidinone class antibacterial with potent antimycobacterial activity. It is being clinically evaluated as a treatment for tuberculosis (TB).
|
|
Bioactivity Comments |
The MIC for in vitro activity against Mycobacterium tuberculosis is 1.5 μg/ml and 2.0 μg/ml against Mycobacterium kansasii [3]. In a mouse infection model, TBI-223 was found to be at least as efficacious and potentially safer than linezolid [2]. The compound has also been found to have activity in mouse models of methicillin-resistant Staphylococcus aureus (MRSA) infections [1]. |